XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($)
$ in Millions
Jul. 31, 2021
Apr. 30, 2021
Oct. 31, 2020
Jul. 31, 2020
Apr. 30, 2020
Oct. 31, 2019
Liabilities, Short-term            
Contingent Consideration $ 110 $ 96 $ 0 $ 0 $ 0 $ 0
Fair Value, Measurements, Recurring            
Assets, Long-term            
Total assets measured at fair value 700   797      
Liabilities Long-term            
Total liabilities measured at fair value 149   47      
Fair Value, Measurements, Recurring | Other Current Assets            
Assets Short - term            
Cash equivalents (money market funds) 621   740      
Derivative instruments (foreign exchange contracts) 5   2      
Fair Value, Measurements, Recurring | Other assets            
Assets, Long-term            
Trading securities 33   30      
Other investments 41   25      
Fair Value, Measurements, Recurring | Other accrued liabilities            
Liabilities, Short-term            
Derivative instruments (foreign exchange contracts) 6   17      
Contingent Consideration 62   0      
Fair Value, Measurements, Recurring | Other long-term liabilities            
Liabilities, Short-term            
Contingent Consideration 48   0      
Liabilities Long-term            
Deferred compensation liability 33   30      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)            
Assets, Long-term            
Total assets measured at fair value 664   770      
Liabilities Long-term            
Total liabilities measured at fair value 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets            
Assets Short - term            
Cash equivalents (money market funds) 621   740      
Derivative instruments (foreign exchange contracts) 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets            
Assets, Long-term            
Trading securities 33   30      
Other investments 10   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities            
Liabilities, Short-term            
Derivative instruments (foreign exchange contracts) 0   0      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities            
Liabilities, Short-term            
Contingent Consideration 0   0      
Liabilities Long-term            
Deferred compensation liability 0   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)            
Assets, Long-term            
Total assets measured at fair value 36   27      
Liabilities Long-term            
Total liabilities measured at fair value 39   47      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets            
Assets Short - term            
Cash equivalents (money market funds) 0   0      
Derivative instruments (foreign exchange contracts) 5   2      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets            
Assets, Long-term            
Trading securities 0   0      
Other investments 31   25      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities            
Liabilities, Short-term            
Derivative instruments (foreign exchange contracts) 6   17      
Contingent Consideration 0   0      
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities            
Liabilities, Short-term            
Contingent Consideration 0   0      
Liabilities Long-term            
Deferred compensation liability 33   30      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)            
Assets, Long-term            
Total assets measured at fair value 0   0      
Liabilities, Short-term            
Contingent Consideration 110          
Liabilities Long-term            
Total liabilities measured at fair value 110   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets            
Assets Short - term            
Cash equivalents (money market funds) 0   0      
Derivative instruments (foreign exchange contracts) 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets            
Assets, Long-term            
Trading securities 0   0      
Other investments 0   0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities            
Liabilities, Short-term            
Derivative instruments (foreign exchange contracts) 0   0      
Contingent Consideration     0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.            
Liabilities, Short-term            
Contingent Consideration 62          
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities            
Liabilities, Short-term            
Contingent Consideration     0      
Liabilities Long-term            
Deferred compensation liability 0   $ 0      
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc.            
Liabilities, Short-term            
Contingent Consideration $ 48